PriceTargets.com logo

Twist Bioscience - TWST Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $98.45
  • Forecasted Upside: -28.71%
  • Number of Analysts: 12
  • Breakdown:
  • 2 Sell Ratings
  • 2 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$138.10 As of 09/15/2026 05:00 PM ET
▲ +3.35 (2.49%)

This chart shows the closing price for TWST by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Twist Bioscience Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TWST and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TWST

Analyst Price Target is $98.45
▼ -28.71% Downside Potential
This price target is based on 12 analysts offering 12 month price targets for Twist Bioscience in the last 3 months. The average price target is $98.45, with a high forecast of $144.00 and a low forecast of $41.00. The average price target represents a -28.71% upside from the last price of $138.10.

This chart shows the closing price for TWST for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 12 contributing investment analysts is to moderate buy stock in Twist Bioscience. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
3/24/2025
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
6/22/2025
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
9/20/2025
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 2 sell ratings
Ratings as of
12/19/2025
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 2 sell ratings
Ratings as of
3/19/2026
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
6/17/2026
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
8/16/2026
  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 2 sell ratings
Ratings as of
9/15/2026

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/9/2026BWS FinancialInitiated CoverageSell$45.00
9/9/2026UBS GroupInitiated CoverageNeutral$144.00
8/24/2026GuggenheimReiterated RatingBuy ➝ Buy
8/5/2026Piper SandlerBoost TargetOverweight ➝ Overweight$85.00 ➝ $115.00
8/4/2026Robert W. BairdBoost TargetOutperform ➝ Outperform$113.00 ➝ $115.00
8/3/2026TD CowenReiterated RatingBuy ➝ Buy
7/16/2026Leerink PartnersSet Target$110.00
7/14/2026Canaccord Genuity GroupBoost TargetBuy ➝ Buy$90.00 ➝ $120.00
7/6/2026EvercoreDowngradeOutperform ➝ In-Line$102.00
6/29/2026GuggenheimBoost TargetBuy ➝ Buy$60.00 ➝ $107.00
6/24/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
6/24/2026BarclaysBoost TargetOverweight ➝ Overweight$65.00 ➝ $95.00
6/15/2026TD CowenBoost TargetBuy ➝ Buy$68.00 ➝ $89.00
6/15/2026Canaccord Genuity GroupInitiated CoverageBuy$90.00
6/15/2026UBS GroupSet Target$89.00
6/15/2026TD CowenBoost TargetBuy ➝ Buy$68.00 ➝ $89.00
6/15/2026Canaccord Genuity GroupInitiated CoverageBuy$90.00
6/11/2026Piper SandlerInitiated CoverageOverweight ➝ Overweight$85.00
6/11/2026Piper SandlerInitiated CoverageOverweight ➝ Overweight$85.00
5/22/2026Leerink PartnersSet Target$80.00
5/5/2026GuggenheimBoost TargetBuy ➝ Buy$55.00 ➝ $60.00
5/5/2026Robert W. BairdBoost TargetOutperform ➝ Outperform$50.00 ➝ $65.00
5/5/2026Leerink PartnersUpgradeMarket Perform ➝ Outperform$70.00
5/4/2026BarclaysBoost TargetOverweight ➝ Overweight$55.00 ➝ $65.00
4/14/2026BarclaysBoost TargetOverweight ➝ Overweight$50.00 ➝ $55.00
3/30/2026GuggenheimBoost TargetBuy ➝ Buy$50.00 ➝ $55.00
3/27/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
2/3/2026Robert W. BairdSet Target$50.00
2/3/2026EvercoreBoost TargetOutperform ➝ Outperform$42.00 ➝ $52.00
2/3/2026BarclaysBoost TargetOverweight ➝ Overweight$39.00 ➝ $50.00
1/8/2026TD CowenReiterated RatingBuy ➝ Buy
1/8/2026TD CowenBoost TargetBuy ➝ Buy$32.00 ➝ $43.00
1/5/2026EvercoreReiterated RatingOutperform ➝ Outperform$42.00
12/29/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/22/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/15/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/15/2025BarclaysBoost TargetOverweight ➝ Overweight$37.00 ➝ $39.00
12/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/1/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/19/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
11/17/2025BarclaysLower TargetOverweight ➝ Overweight$40.00 ➝ $37.00
11/13/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
11/3/2025StephensInitiated CoverageOverweight$41.00
11/3/2025StephensInitiated CoverageOverweight$41.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
10/7/2025EvercoreLower TargetOutperform ➝ Outperform$46.00 ➝ $42.00
10/2/2025BarclaysLower TargetOverweight ➝ Overweight$45.00 ➝ $40.00
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
8/4/2025TD CowenReiterated RatingBuy ➝ Buy
8/4/2025EvercoreSet Target$46.00
5/6/2025The Goldman Sachs GroupLower TargetBuy ➝ Buy$55.00 ➝ $48.00
5/6/2025GuggenheimReiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
5/6/2025Robert W. BairdLower TargetOutperform ➝ Outperform$54.00 ➝ $44.00
5/6/2025JPMorgan Chase & Co.Lower TargetUnderweight ➝ Underweight$40.00 ➝ $33.00
4/10/2025BarclaysLower TargetOverweight ➝ Overweight$58.00 ➝ $45.00
3/28/2025GuggenheimSet Target$50.00
2/4/2025ScotiabankReiterated RatingOutperform ➝ Outperform
2/4/2025JPMorgan Chase & Co.Boost TargetUnderweight ➝ Underweight$35.00 ➝ $40.00
2/4/2025ScotiabankBoost TargetSector Outperform ➝ Sector Outperform$54.00 ➝ $62.00
2/4/2025Robert W. BairdBoost TargetOutperform ➝ Outperform$48.00 ➝ $54.00
2/3/2025BarclaysSet TargetOverweight ➝ Overweight$58.00
12/13/2024Wolfe ResearchInitiated CoverageOutperform$60.00
11/26/2024TD CowenReiterated RatingBuy ➝ Buy$58.00 ➝ $58.00
11/19/2024BarclaysLower TargetOverweight ➝ Overweight$55.00 ➝ $52.00
11/19/2024ScotiabankBoost TargetSector Outperform ➝ Sector Outperform$50.00 ➝ $54.00
11/19/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$46.00 ➝ $48.00
10/17/2024Leerink PartnersBoost TargetMarket Perform ➝ Market Perform$45.00 ➝ $48.00
10/1/2024EvercoreBoost TargetOutperform ➝ Outperform$52.00 ➝ $56.00
8/5/2024BarclaysLower TargetOverweight ➝ Overweight$60.00 ➝ $55.00
8/5/2024JPMorgan Chase & Co.Boost TargetUnderweight ➝ Underweight$28.00 ➝ $35.00
8/5/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$40.00 ➝ $46.00
7/9/2024The Goldman Sachs GroupBoost TargetBuy ➝ Buy$45.00 ➝ $55.00
6/28/2024BarclaysBoost TargetOverweight ➝ Overweight$45.00 ➝ $60.00
6/13/2024TD CowenBoost TargetBuy ➝ Buy$55.00 ➝ $65.00
6/4/2024GuggenheimInitiated CoverageBuy$53.00
5/6/2024ScotiabankBoost TargetSector Outperform ➝ Sector Outperform$43.00 ➝ $48.00
5/3/2024EvercoreBoost TargetOutperform ➝ Outperform$46.00 ➝ $50.00
5/3/2024BarclaysBoost TargetOverweight ➝ Overweight$40.00 ➝ $45.00
5/3/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$39.00 ➝ $40.00
4/10/2024BarclaysLower TargetOverweight ➝ Overweight$45.00 ➝ $40.00
2/5/2024ScotiabankBoost TargetSector Outperform ➝ Sector Outperform$30.00 ➝ $43.00
1/25/2024BarclaysBoost TargetOverweight ➝ Overweight$30.00 ➝ $45.00
1/17/2024The Goldman Sachs GroupUpgradeNeutral ➝ Buy$25.00 ➝ $45.00
9/27/2023Berenberg BankInitiated CoverageBuy$27.00
8/7/2023Robert W. BairdBoost Target$18.00 ➝ $27.00
8/7/2023BarclaysBoost TargetOverweight ➝ Overweight$20.00 ➝ $26.00
5/8/2023Robert W. BairdLower Target$29.00 ➝ $18.00
5/8/2023BarclaysLower Target$32.00 ➝ $20.00
4/19/2023The Goldman Sachs GroupLower TargetNeutral$43.00 ➝ $20.00
2/6/2023The Goldman Sachs GroupLower TargetNeutral$50.00 ➝ $43.00
2/6/2023BarclaysLower TargetOverweight$37.00 ➝ $32.00
2/6/2023Robert W. BairdLower Target$33.00 ➝ $29.00
1/29/2023BarclaysLower TargetOverweight$43.00 ➝ $37.00
1/4/2023ScotiabankInitiated CoverageSector Outperform$33.00
1/3/2023EvercoreUpgradeIn-Line ➝ Outperform$28.00 ➝ $36.00
11/21/2022Robert W. BairdLower TargetOutperform$56.00 ➝ $33.00
11/21/2022BarclaysLower TargetOverweight$45.00 ➝ $43.00
11/21/2022Leerink PartnersLower TargetMarket Perform$45.00 ➝ $30.00
10/7/2022Leerink PartnersLower TargetMarket Perform$50.00 ➝ $45.00
10/6/2022BarclaysLower TargetOverweight$55.00 ➝ $45.00
8/8/2022Robert W. BairdBoost Target$43.00 ➝ $56.00
8/8/2022BarclaysBoost TargetOverweight$45.00 ➝ $55.00
8/8/2022Leerink PartnersBoost TargetMarket Perform$45.00 ➝ $50.00
7/13/2022BarclaysBoost TargetOverweight$40.00 ➝ $45.00
5/9/2022BarclaysLower Target$60.00 ➝ $40.00
5/6/2022Robert W. BairdLower Target$70.00 ➝ $43.00
4/20/2022BarclaysLower Target$75.00 ➝ $60.00
4/13/2022The Goldman Sachs GroupLower TargetNeutral$105.00 ➝ $55.00
2/7/2022Leerink PartnersLower TargetMarket Perform$110.00 ➝ $70.00
2/7/2022Robert W. BairdLower Target$113.00 ➝ $70.00
2/7/2022BarclaysLower TargetOverweight$130.00 ➝ $75.00
11/23/2021Robert W. BairdLower TargetOutperform$130.00 ➝ $113.00
(Data available from 9/15/2021 forward)

News Sentiment Rating

1.20 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/17/2026
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/19/2026
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/18/2026
  • 10 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/18/2026
  • 4 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/17/2026
  • 4 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/17/2026
  • 4 very positive mentions
  • 15 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/16/2026
  • 33 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/15/2026

Current Sentiment

  • 33 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Twist Bioscience logo
Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $138.10
Low: $131.54
High: $138.93

50 Day Range

MA: $115.15
Low: $85.47
High: $153.10

52 Week Range

Now: $138.10
Low: $23.30
High: $155.44

Volume

1,287,919 shs

Average Volume

1,582,556 shs

Market Capitalization

$8.66 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.22

Frequently Asked Questions

What sell-side analysts currently cover shares of Twist Bioscience?

The following Wall Street analysts have issued reports on Twist Bioscience in the last year: Barclays PLC, BWS Financial, Canaccord Genuity Group Inc., Evercore Inc, Guggenheim, Leerink Partners, Piper Sandler, Robert W. Baird, Stephens, TD Cowen, UBS Group AG, and Weiss Ratings.
View the latest analyst ratings for TWST.

What is the current price target for Twist Bioscience?

0 Wall Street analysts have set twelve-month price targets for Twist Bioscience in the last year. Their average twelve-month price target is $98.45, suggesting a possible downside of 27.8%. UBS Group AG has the highest price target set, predicting TWST will reach $144.00 in the next twelve months. Stephens has the lowest price target set, forecasting a price of $41.00 for Twist Bioscience in the next year.
View the latest price targets for TWST.

What is the current consensus analyst rating for Twist Bioscience?

Twist Bioscience currently has 2 sell ratings, 2 hold ratings and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for TWST.

What other companies compete with Twist Bioscience?

Other companies that are similar to Twist Bioscience include Ginkgo Bioworks, Illumina, Mettler-Toledo International, Medpace and Revvity. Learn More about companies similar to Twist Bioscience.

How do I contact Twist Bioscience's investor relations team?

Twist Bioscience's physical mailing address is 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA, 94080. The company's listed phone number is (800) 719-0671 and its investor relations email address is [email protected]. The official website for Twist Bioscience is www.twistbioscience.com. Learn More about contacing Twist Bioscience investor relations.